Valsartan plus hydrochlorothiazide for first-line therapy in hypertension

References

• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119(3), E21–E181 (2009).
   PubMed Web of Science ®Google Scholar
• Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am. J. Hypertens.13(1 Pt 2), S3–S10 (2000).
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet371(9623), 1513–1518 (2008).
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension49(1), 69–75 (2007).
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch. Intern. Med.160(15), 2281–2286 (2000).
   PubMed Web of Science ®Google Scholar
• Neutel JM. The role of combination therapy in the management of hypertension. Nephrol. Dial. Transplant.21(6), 1469–1473 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman RD, Zou GY, Vandervoort MK et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension53(4), 646–653 (2009).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Os I, Hoieggen A et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am. J. Cardiovasc. Drugs5(1), 17–22 (2005).
   PubMedGoogle Scholar
• Zappe DH, Sowers JR, Hsueh WA et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J. Clin. Hypertens. (Greenwich)10(12), 894–903 (2008).
   PubMed Web of Science ®Google Scholar
• Neutel JM. The role of combination therapy in the management of hypertension. Nephrol. Dial. Transplant21(6), 1469–1473 (2006).
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Herrington D, Ouyang P et al. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J. Clin. Hypertens. (Greenwich)8(10), 692–698 (2006).
   PubMedGoogle Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet363(9426), 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21(5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol.44(6), 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijisq L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens.22(4), 847–857 (2004).
   PubMed Web of Science ®Google Scholar
• Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag. Care9(9 Suppl.), 2–6 (2000).
   PubMedGoogle Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am. J. Hypertens.19(11), 1190–1196 (2006).
   PubMed Web of Science ®Google Scholar
• Brixner DI, Jackson KC, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr. Med. Res. Opin.24(9), 2597–2607 (2008).
   PubMed Web of Science ®Google Scholar
• Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin. Ther.30(8), 1558–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs57(5), 751–755 (1999).
   PubMed Web of Science ®Google Scholar
• Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs62(13), 1983–2005 (2002).
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Brunner H, Irwin R et al.; Losartan Cough Study Group. Effects of modulators of the renin–angiotensin–aldosterone system on cough. J. Hypertens.12(12), 1387–1393 (1994).
   PubMed Web of Science ®Google Scholar
• Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs54(2), 299–311 (1997).
   PubMed Web of Science ®Google Scholar
• Fuchs M, Mallin SR, Irie S, Hernando L, Moyer JH. A review of the pharmacology and clinical observations of hydrochlorothiazide. Arch. Intern. Med.105, 39–50 (1960).
   PubMedGoogle Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA202(11), 1028–1034 (1967).
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA213(7), 1143–1152 (1970).
   PubMed Web of Science ®Google Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension43(1), 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich)4(6), 393–404 (2002).
   PubMedGoogle Scholar
• Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension42(3), 239–246 (2003).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA265(24), 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Amery A, Birkenhäger W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1(8442), 1349–1354 (1985).
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ304(6824), 405–412 (1992).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356(9227), 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs66(14), 1881–1901 (2006).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349(20), 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet369(9571), 1431–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Benz JR, Black HR, Graff A et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J. Hum. Hypertens.12(12), 861–866 (1998).
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin. Ther.29(1), 61–73 (2007).
   PubMed Web of Science ®Google Scholar
• Nash DT, Crikelair N, Zappe D. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies. Curr. Med. Res. Opin.24(9), 2617–2626 (2008).
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Wright Jr JT, Samuel R et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press. Monit.14(3), 112–120 (2009).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Glazer RD, Pettyjohn FS et al. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr. Med. Res. Opin.24(8), 2303–2311 (2008).
   PubMed Web of Science ®Google Scholar
• White WB, Calhoun DA, Samuel R et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J. Clin. Hypertens. (Greenwich)10(6), 450–458 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension48(1), 73–79 (2006).
   PubMed Web of Science ®Google Scholar
• Weir MR, Levy D, Crikelair N et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am. J. Hypertens.20(7), 807–815 (2007).
   PubMed Web of Science ®Google Scholar
• Khan NA, Hemmelgarn B, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2–therapy. Can. J. Cardiol.25(5), 287–298 (2009).
   PubMed Web of Science ®Google Scholar
• Amar J, Vaur L, Perret M et al. Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J. Hypertens.20(4), 779–784 (2002).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sowers JR, Ferdinand KC. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev. Cardiol.11(1), 42–49 (2008).
   PubMedGoogle Scholar
• Nasser SA, Lai Z, O’Connor S, Liu X, Flack JM. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr. Hypertens. Rep.10(5), 398–404 (2008).
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation115(21), 2761–2788 (2007).
   PubMed Web of Science ®Google Scholar
• Aulakh GK, Sodhi RK, Singh M. An update on nonpeptide angiotensin receptor antagonists and related RAAS modulators. Life Sci.81(8), 615–639 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev. Cardiovasc. Ther.7(3), 251–257 (2009).
   PubMedGoogle Scholar